Sangui Biotech International Inc (SGBI) Financial Statements (2024 and earlier)

Company Profile

Business Address 352 SOUTH 200 WEST
FARMINGTON, UT 84025
State of Incorp. CO
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
12/31/2021
Q2
9/30/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments973068813
Cash and cash equivalents973068813
Receivables 176023293124
Prepaid expense1471218169
Other undisclosed current assets4 20 3
Total current assets:4473681155649
Noncurrent Assets
Property, plant and equipment000111
Other undisclosed noncurrent assets 555463717885
Total noncurrent assets:555463727986
TOTAL ASSETS:99127131187135135
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 8    
Taxes payable4  
Accrued liabilities 4    
Debt724660708747767746
Due to related parties837272726966
Other liabilities     1 
Other undisclosed current liabilities184171156157147157
Total current liabilities:991911936976984968
Noncurrent Liabilities
Long-term debt and lease obligation4478901025358
Long-term debt, excluding current maturities44434955  
Liabilities, other than long-term debt34     
Operating lease, liability343541485358
Other undisclosed noncurrent liabilities  (35) (48)(53)(58)
Total noncurrent liabilities:7878901025358
Total liabilities:1,0699891,0261,0781,0371,027
Equity
Equity, attributable to parent(315)(207)(239)(238)(250)(239)
Common stock33,12533,12533,12533,12533,10033,100
Treasury stock, value(19)(19)(19)(19)(19)(19)
Additional paid in capital4,5134,5134,5134,5134,5134,513
Accumulated other comprehensive income10010597908989
Accumulated deficit(38,034)(37,931)(37,955)(37,947)(37,932)(37,922)
Equity, attributable to noncontrolling interest(655)(654)(656)(653)(653)(653)
Total equity:(970)(862)(895)(892)(902)(892)
TOTAL LIABILITIES AND EQUITY:99127131187135135

Income Statement (P&L) ($ in thousands)

3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
12/31/2021
Q2
9/30/2021
Q1
Revenues114111182219
Gross profit:114111182219
Operating expenses(38)(57)(58)(46)(42)(62)
Operating loss:(27)(16)(48)(28)(20)(44)
Nonoperating income (expense)(76)4138131016
Gain (loss), foreign currency transaction, before tax(71)4643221420
Interest and debt expense(5)(5)(4)(14)(9)(5)
Income (loss) from continuing operations:(108)20(14)(29)(20)(33)
Income (loss) before gain (loss) on sale of properties:20(14)(29)(20)(33)
Other undisclosed net income5541495
Net income (loss):(103)25(10)(15)(10)(28)
Other undisclosed net income (loss) attributable to parent1(2)2101
Net income (loss) available to common stockholders, diluted:(102)23(7)(15)(10)(27)

Comprehensive Income ($ in thousands)

3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
12/31/2021
Q2
9/30/2021
Q1
Net income (loss):(103)25(10)(15)(10)(28)
Other comprehensive income (loss)109(33)3141128
Comprehensive income (loss), net of tax, attributable to parent:5(9)(7)(1)00

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: